Mixed Earnings Outlook For Top Korean Pharma Firms
This article was originally published in PharmAsia News
Major South Korean pharma firms are likely to post higher sales in the calendar first quarter driven by brisk exports, but mixed operating profits amid few signs of a recovery in the domestic prescription market. Increased spending for R&D stemming from the industry’s push to develop new drugs is also damping companies’ bottom lines, according to securities firms.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.